Efficacy of an AS03 A-adjuvanted split H5N1 influenza vaccine against an antigenically distinct low pathogenic H5N1 virus in pigs

Vaccine

Volumn 30, Issue 37, 2012, Pages 5557-5563

  De Vleeschauwer, Annebel R ^a,c   Baras, Benoît ^b   Kyriakis, Constantinos S ^a,d   Jacob, Valérie ^b   Planty, Camille ^b   Giannini, Sandra L ^b   Mossman, Sally ^b   Van Reeth, Kristien ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c VETERINARY AND AGROCHEMICAL RESEARCH CENTRE   (Belgium)

^d UNIVERSITY OF THESSALY   (Greece)

Author keywords

Animal models for influenza; AS03 A adjuvant; Cross protection; Efficacy; H5N1 avian influenza virus; Pigs; Prepandemic vaccine

Indexed keywords

ADJUVANT; AMINO ACID; ANTIBODY; AS 03A; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA H5N1 SPLIT VIRION VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; SIALIDASE INHIBITING ANTIBODY; SWINE INFLUENZA VACCINE; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DRUG EFFICACY; HEMAGGLUTINATION INHIBITION TEST; INFLUENZA VIRUS A H5N1; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; SEQUENCE HOMOLOGY; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; CELLULAR IMMUNITY; DISEASE MODEL; HUMAN; IMMUNOLOGY; INFLUENZA; LUNG; PATHOGENICITY; PATHOLOGY; SWINE; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LUNG; SUS SCROFA;

EID: 84864303662     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.028     Document Type: Article

References (34)

1. World Health Organisation (WHO). Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO; 2003-2012. Available at: http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/index.html.
2. Subbarao K., Luke C. H5N1 viruses and vaccines. PLoS Pathog 2007, 3:e40.
3. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9:1057-1071.
4. European Medicines Agency (EMEA). Prepandrix. GlaxoSmithKline Biologicals SA, Rixensart, Belgium. Available at: http://www.emea.europa.eu/pdfs/human/opinion/Prepandrix_33405509en.pdf or http://www.emea.europa.eu/humandocs/Humans/EPAR/prepandrix/prepandrix.htm.
5. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007, 370:580-589.
6. Leroux-Roels I., Bernhard R., Gerard P., Drame M., Hanon E., Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3:e1665.
7. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 1:e1401.
8. Van Reeth K., Brown I.H., Olsen C.W. Swine influenza. Diseases of swine 2012, 557-571. Wiley-Blackwell Publishing Company, Hoboken, NJ. 10th ed. J. Zimmerman, L. Karriker, A. Ramirez, K.J. Schwartz, G. Stevenson (Eds.).
9. Choi Y.K., Nguyen T.D., Ozaki H., Webby R.J., Puthavathana P., Buranathal C., et al. Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004. J Virol 2005, 79:10821-10825.
10. Nidom C.A., Takano R., Yamada S., Sakai-Tagawa Y., Daulay S., Aswadi D., et al. Influenza A (H5N1) viruses from pigs, Indonesia. Emerg Infect Dis 2010, 16:1515-1523.
11. Shi W.F., Gibbs M.J., Zhang Y.Z., Zhang Z., Zhao X.M., Jin X., et al. Genetic analysis of four porcine avian influenza viruses isolated from Shandong, China. Arch Virol 2008, 153:211-217.
12. Lee J.H., Pascua P.N., Song M.S., Baek Y.H., Kim C.J., Choi H.W., et al. Isolation and genetic characterization of H5N2 influenza viruses from pigs in Korea. J Virol 2009, 83:4205-4215.
13. Lipatov A.S., Kwon Y.K., Sarmento L.V., Lager K.M., Spackman E., Suarez D.L., et al. Domestic pigs have low susceptibility to H5N1 highly pathogenic avian influenza viruses. PLoS Pathog 2008, 4:e1000102.
14. De Vleeschauwer A., Van Poucke S., Braeckmans D., Van Doorsselaere J., Van Reeth K. Efficient transmission of swine-adapted but not wholly avian influenza viruses among pigs and from pigs to ferrets. J Infect Dis 2009, 200:1884-1892.
15. Van Reeth K., Braeckmans D., Cox E., Van Borm S., van den Berg T., Goddeeris B., et al. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus. Vaccine 2009, 27:6330-6339.
16. Sandbulte M.R., Gao J., Straight T.M., Eichelberger M.C. A miniaturized assay for influenza neuraminidase-inhibiting antibodies using reverse genetics-derived antigens. Influenza Other Respir Viruses 2008, 3:233-240.
17. De Vleeschauwer A.R., Van Poucke S.G., Karasin A.I., Olsen C.W., Van Reeth K. Cross-protection between antigenically distinct H1N1 swine influenza viruses from Europe and North America. Influenza Other Respir Viruses 2011, 5:115-122.
18. Atanasova K., Van Gucht S., Barbé F., Duchateau L., Van Reeth K. Lipoteichoic acid from Staphylococcus aureus exacerbates respiratory disease in porcine respiratory coronavirus-infected pigs. Vet J 2011, 188:210-215.
19. Cattoli G., Fusaro A., Monne I., Capua I. H5N1 virus evolution in Europe-an updated overview. Viruses 2009, 1:1351-1363.
20. Pfeiffer D.U., Jotte M., Roland-Holst D., Inui K., Tung N., Zilberman D. Implications of global and regional patterns of highly pathogenic avian influenza virus H5N1 clades for risk management. Vet J 2011, 190:309-316.
21. Moris P., van der Most R., Leroux-Roels I., Clement F., Dramé M., Hanon E., et al. H5N1 influenza vaccine formulated with AS03 induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2010, 10.1007/s10875-010-9490-6.
22. Johansson B.E., Matthews J.T., Kilbourne E.D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 1998, 16:1009-1015.
23. Murphy B.R., Kasel J.A., Chanock R.M. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972, 286:1329-1332.
24. Couch R.B., Kasel J.A., Gerin J.L., Schulman J.L., Kilbourne E.D. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974, 129:411-420.
25. Fritz R., Sabarth N., Kiermayr S., Hohenadl C., Howard M.K., Ilk R., et al. A Vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 2012, 205:28-34.
26. De Vleeschauwer A., Atanasova K., Van Borm S., van den Berg T., Rasmussen T.B., Uttenthal A., et al. Comparative pathogenesis of an avian H5N2 and a swine H1N1 influenza virus in pigs. PLoS One 2009, 4:e6662.
27. Kyriakis C.S., De Vleeschauwer A., Barbé F., Bublot M., Van Reeth K. Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs. Vaccine 2009, 27:2258-2264.
28. Dyce K.M., Sack W.O., Wensing C.J.G. The vertebral column, back and thorax of the pig. Textbook of veterinary anatomy 2002, Elsevier Science, pp. 772-775. 3rd ed.
29. Barnard D.L. Animal models for the study of influenza pathogenesis and therapy. Antiviral Res 2009, 82:110-122.
30. van der Laan J.W., Herberts C., Lambkin-Williams R., Boyers A., Mann A.J., Oxford J. Animal models in influenza vaccine testing. Expert Rev Vaccines 2008, 7:783-793.
31. Manzoor R., Sakoda Y., Nomura N., Tsuda Y., Ozaki H., Okamatsu M., et al. PB2 protein of a highly pathogenic avian influenza virus strain A/chicken/Yamaguchi/7/2004 (H5N1) determines its replication potential in pigs. J Virol 2009, 83:1572-1578.
32. Van Reeth K., Nauwynck H., Pensaert M. Bronchoalveolar interferon-alpha, tumor necrosis factor-alpha, interleukin-1, and inflammation during acute influenza in pigs: a possible model for humans. J Infect Dis 1998, 177:1076-1079.
33. Kuiken T., Taubenberger J. Pathology of human influenza revisited. Vaccine 2008, 26:59-66.
34. Peiris J.S.M., de Jong M.D., Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin Microbiol Rev 2007, 20:234-267.